For the level of ESMO annual congress, a LBA oral presentation, there is no way any of that foggy looking result package will be accepted.
By Sep, the ORR from part A would be very matured and PFS together with OS profile should be surfacing out.
Most importantly, after the whole oncology field have a good discussion on this Eftilagimod plus PD1 combo, you can imagine how FDA and EMA are thinking on that angle.
For the level of ESMO annual congress, a LBA oral presentation,...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $447.2M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.5¢ | 30.5¢ | $156.9K | 508.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 151783 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 288270 | 31 |
View Market Depth
| Last trade - 12.29pm 13/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |